Cargando…

High-Temperature Short-Time Treatment of Human Milk for Bacterial Count Reduction

Background: Human milk (HM) for preterm infants will often be pasteurized for cytomegalovirus (CMV) inactivation and reduction of its bacterial count. High-temperature short-time (HTST) treatment compared to standard Holder pasteurization (HoP) reduces the impact of heat treatment on bioactive HM pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Klotz, Daniel, Schreiner, Marie, Falcone, Valeria, Jonas, Daniel, Kunze, Mirjam, Weber, Andrea, Fuchs, Hans, Hentschel, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277678/
https://www.ncbi.nlm.nih.gov/pubmed/30538974
http://dx.doi.org/10.3389/fped.2018.00359
_version_ 1783378206149050368
author Klotz, Daniel
Schreiner, Marie
Falcone, Valeria
Jonas, Daniel
Kunze, Mirjam
Weber, Andrea
Fuchs, Hans
Hentschel, Roland
author_facet Klotz, Daniel
Schreiner, Marie
Falcone, Valeria
Jonas, Daniel
Kunze, Mirjam
Weber, Andrea
Fuchs, Hans
Hentschel, Roland
author_sort Klotz, Daniel
collection PubMed
description Background: Human milk (HM) for preterm infants will often be pasteurized for cytomegalovirus (CMV) inactivation and reduction of its bacterial count. High-temperature short-time (HTST) treatment compared to standard Holder pasteurization (HoP) reduces the impact of heat treatment on bioactive HM proteins while effectively inactivating CMV. No data are available for the efficacy of bacterial count reduction using HTST treatments that are available for clinical use. Objective: To test the antiviral and antibacterial efficacy of HTST treatment protocols in HM using a modified HTST treatment device compared to standard HoP. Methods: Holder pasteurized 95 mL HM samples were inoculated with Staphylococcus aureus (ATCC 6538), Enterococcus faecalis (ATCC 29212), Pseudomonas aeruginosa (ATCC 27853), Serratia marcescens (Smarc 00697), two different strains of Klebsiella pneumoniae (ATCC 700603 and Kpn 01605) or spiked with 2 × 10(5) 50% tissue culture infective dose of CMV (AD169) and subsequently subjected to HoP (62.5°C/30 min) or HTST treatment (62°C/5 s, 62°C/15 s, 72°C/5 s, 72°C/15 s, 87°C/2 s, and 87°C/5 s). Bacterial count was determined after treated HM was cultured for 24 h. CMV infectivity was determined by the number of specific CMV immediate early antigen stained nuclei after inoculating human fibroblasts with appropriately prepared HM samples. Results: Holder pasteurized samples revealed no growth after 24 h incubation. Viable bacterial cultures were retrieved from all tested strains after HTST treatment with the default HTST protocol (62°C/5 s) that is available for clinical use. Using other time-temperature combinations, growth rates of S. aureus, E. faecalis, P. aeruginosa, K. pneumoniae, K. pneumonia, and S. marcescens were depending on treatment time, treatment temperature, bacterial genera and strain. Only after treatment temperatures above 72°C no bacterial growth was observed. CMV was inactivated by any tested time-temperature combination. Conclusions: HTST treatment inactivates CMV in 95 mL HM samples but is less effective than HoP in bacterial count reduction at a time-temperature combination of 62°C/5 s. For a reliable bacterial count reduction HTST treatment at 87°C was required in this study.
format Online
Article
Text
id pubmed-6277678
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62776782018-12-11 High-Temperature Short-Time Treatment of Human Milk for Bacterial Count Reduction Klotz, Daniel Schreiner, Marie Falcone, Valeria Jonas, Daniel Kunze, Mirjam Weber, Andrea Fuchs, Hans Hentschel, Roland Front Pediatr Pediatrics Background: Human milk (HM) for preterm infants will often be pasteurized for cytomegalovirus (CMV) inactivation and reduction of its bacterial count. High-temperature short-time (HTST) treatment compared to standard Holder pasteurization (HoP) reduces the impact of heat treatment on bioactive HM proteins while effectively inactivating CMV. No data are available for the efficacy of bacterial count reduction using HTST treatments that are available for clinical use. Objective: To test the antiviral and antibacterial efficacy of HTST treatment protocols in HM using a modified HTST treatment device compared to standard HoP. Methods: Holder pasteurized 95 mL HM samples were inoculated with Staphylococcus aureus (ATCC 6538), Enterococcus faecalis (ATCC 29212), Pseudomonas aeruginosa (ATCC 27853), Serratia marcescens (Smarc 00697), two different strains of Klebsiella pneumoniae (ATCC 700603 and Kpn 01605) or spiked with 2 × 10(5) 50% tissue culture infective dose of CMV (AD169) and subsequently subjected to HoP (62.5°C/30 min) or HTST treatment (62°C/5 s, 62°C/15 s, 72°C/5 s, 72°C/15 s, 87°C/2 s, and 87°C/5 s). Bacterial count was determined after treated HM was cultured for 24 h. CMV infectivity was determined by the number of specific CMV immediate early antigen stained nuclei after inoculating human fibroblasts with appropriately prepared HM samples. Results: Holder pasteurized samples revealed no growth after 24 h incubation. Viable bacterial cultures were retrieved from all tested strains after HTST treatment with the default HTST protocol (62°C/5 s) that is available for clinical use. Using other time-temperature combinations, growth rates of S. aureus, E. faecalis, P. aeruginosa, K. pneumoniae, K. pneumonia, and S. marcescens were depending on treatment time, treatment temperature, bacterial genera and strain. Only after treatment temperatures above 72°C no bacterial growth was observed. CMV was inactivated by any tested time-temperature combination. Conclusions: HTST treatment inactivates CMV in 95 mL HM samples but is less effective than HoP in bacterial count reduction at a time-temperature combination of 62°C/5 s. For a reliable bacterial count reduction HTST treatment at 87°C was required in this study. Frontiers Media S.A. 2018-11-27 /pmc/articles/PMC6277678/ /pubmed/30538974 http://dx.doi.org/10.3389/fped.2018.00359 Text en Copyright © 2018 Klotz, Schreiner, Falcone, Jonas, Kunze, Weber, Fuchs and Hentschel. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Klotz, Daniel
Schreiner, Marie
Falcone, Valeria
Jonas, Daniel
Kunze, Mirjam
Weber, Andrea
Fuchs, Hans
Hentschel, Roland
High-Temperature Short-Time Treatment of Human Milk for Bacterial Count Reduction
title High-Temperature Short-Time Treatment of Human Milk for Bacterial Count Reduction
title_full High-Temperature Short-Time Treatment of Human Milk for Bacterial Count Reduction
title_fullStr High-Temperature Short-Time Treatment of Human Milk for Bacterial Count Reduction
title_full_unstemmed High-Temperature Short-Time Treatment of Human Milk for Bacterial Count Reduction
title_short High-Temperature Short-Time Treatment of Human Milk for Bacterial Count Reduction
title_sort high-temperature short-time treatment of human milk for bacterial count reduction
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277678/
https://www.ncbi.nlm.nih.gov/pubmed/30538974
http://dx.doi.org/10.3389/fped.2018.00359
work_keys_str_mv AT klotzdaniel hightemperatureshorttimetreatmentofhumanmilkforbacterialcountreduction
AT schreinermarie hightemperatureshorttimetreatmentofhumanmilkforbacterialcountreduction
AT falconevaleria hightemperatureshorttimetreatmentofhumanmilkforbacterialcountreduction
AT jonasdaniel hightemperatureshorttimetreatmentofhumanmilkforbacterialcountreduction
AT kunzemirjam hightemperatureshorttimetreatmentofhumanmilkforbacterialcountreduction
AT weberandrea hightemperatureshorttimetreatmentofhumanmilkforbacterialcountreduction
AT fuchshans hightemperatureshorttimetreatmentofhumanmilkforbacterialcountreduction
AT hentschelroland hightemperatureshorttimetreatmentofhumanmilkforbacterialcountreduction